Suppliers / Graviti Pharmaceuticals

Graviti Pharmaceuticals

India 560 employees Updated 9 July 2026

Graviti Pharmaceuticals is an API and finished-dose manufacturer based in India. It holds 2 active US drug master files. Its most recent recorded inspection, by US FDA, closed on 3 February 2023 as NAI. Customs aggregates show $60.3M of exports covering 2,467 molecules to 2 destinations in 2025.

2
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
2
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 3 February 2023 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Sangareddy, India 3012932394

What they file, and where

Molecule Regulators Docs
Pantoprazole US FDA 2

Also appears on these molecule pages

Glipizide finished dose Pantoprazole API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 2 None

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $14.4M 1
2025 Not reported $60.3M 2
2024 Not reported $58.1M 2
2023 Not reported $52.5M 2

Export figures are customs aggregates. We do not publish the identity of any buyer.

Questions about Graviti Pharmaceuticals

Does Graviti Pharmaceuticals hold a US DMF or a CEP?
Graviti Pharmaceuticals holds 2 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Graviti Pharmaceuticals FDA-registered?
One site operated by Graviti Pharmaceuticals carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Graviti Pharmaceuticals's last inspection go?
The most recent inspection on record closed on 3 February 2023 as NAI (No Action Indicated: nothing objectionable was found). 1 inspection is on file.
Where does Graviti Pharmaceuticals manufacture?
1 registered site is on record, in India (Sangareddy). Every site is listed on this page with the register it came from.
What does Graviti Pharmaceuticals make?
1 molecule is on record against Graviti Pharmaceuticals, including Pantoprazole. Each links through to that molecule's full manufacturer list.
Where does Graviti Pharmaceuticals file?
Filings are on record with US FDA, 2 in total.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Graviti Pharmaceuticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 3 February 2023.

Comparable suppliers

Ambition Pharma also in India Andhra Organics also in India Anjan Drug also in India Anthem Biosciences also in India Asian Herbex also in India

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
Customs aggregates
Export values, molecule and destination counts